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Abstract 
CRADA #95-CR-09 
Assist in determining the effectiveness of Boron Neutron Capture Therapy (BNCT) 
as a treatment for a variety of different types of cancer using highly advanced 
boronated pharmaceuticals. 
CRADA No. 95-CR-09 Final Report: 
Date of Completion: 
Abstract: 
CRADA No. 95-CR-09 among the LITCO - now Bechtel BWXT Idaho, LLC; a private 
company, Neutron Therapies Limited Liability Company, NTL formerly Ionix Corporation; 
and Washington State University was established in 1996 to further the development of 
BNCT. NTL has established a laboratory for the synthesis, under U.S. FDA approved current 
Good Manufacturing Practices (cGMP) guidelines, of key boron intermediates and final 
boron agents for BNCT. The company has focused initially on the development of the 
compound GB-1 0 (Na2B loHlo) as the first boron agent of interest. An Investigational New 
Drug (TND) application for GB-10 has been filed and approved by the FDA for a Phase I 
human biodistribution trial in patients with non-small cell lung cancer and glioblastoma 
multiforme at UW under the direction of Professor Keith Stelzer, Principal Investigator (PI). 
These trials are funded by NTL under a contract with the UW, Department of Radiation 
Oncology, and the initial phases are nearing completion. Initial results show that boron-10 
concentrations on the order of 100 micrograms per gram (100 ppm) can be achieved and 
maintained in blood with no indication of toxicity. 
Subject CRADA No. 95-CR-09 Inventions: 
Initial review of intellectual property associated with this CRADA suggested six possible 
inventions leading to copyright asserted software andlor patents. However, after careful 
review of the CRADA's scope of work, designated funding, the timing of inventions and 
their reduction to practice, only one patent was found that is directly attributable to CRADA 
No. 95-CR-09. This one is LIT-PI-261 - Compact Isocentric System for Delivery of Neutron 
Beams for Medical Therapy, US Patent No. 5,920,601. It issued on 1012 111997. 
Benefits: 
The partners have achieved a number of significant milestones. These include: 
1. Development of a modified neutron production target assembly for the UW facility that 
provides improved erformance of the system for applications involving BNCT-enhanced 
F'NT. Prior efforts1' to modify light-ion accelerator based FNT facilities for optimization of 
BNCT enhancement have generally focused either on degradation of the charged particle 
beam before it impinges on the neutron production region of the target, or on partial 
moderation and filtration of the neutron beam after it exits the target. These projects have 
produced neutron beams that offer enhanced BNCT components of the total dose, but this 
has tended to be accomplished at the expense of degradation of the performance of the 
background fast-neutron beam, typically manifested by a reduction in the half-value depth 
for the fast-neutron dose component. However, a more promising approach involving a 
--- . - - - --- - . . - . . 
case. In addition, decaborane sinthesizeh from boron that & enriched in the isotope "B is 
required for BNCT purposes. Chemists at the INEEL developed an improved process for 
synthesizing enriched decaborane in a manner that can be safely and efficiently done in a 
standard chemical laboratory. This process has been transferred under license to NTL. 
3. Establishment, under U.S. FDA cGMP guidelines, of a process for synthesizing 
decaborane as well as the first derived boron agent of interest for human clinical trials of 
NCT-enhanced FNT for certain types of lung and brain tumors. The decaborane synthesis 
process licensed by INEEL to NTL is now fully operational, under the FDA cGMP 
guidelines in laboratories operated by NTL. In addition, GB-10 is also being synthesized and 
packaged as a sterile, injectable drug, and packaged for human applications. As noted 
previously, NTL has obtained FDA approval of an IND to conduct initial human 
biodistribution studies of GB-10 for treatment of non-small cell lung tumors and 
glioblastoma multiforme, and for the fast neutron NCT-augmented brain tumor radiation 
trials. 
4. Enhancement of computational dosimetry and treatment planning software originally 
developed by INEEL for epithermal-neutron BNCT to allow applicability to all forms of 
neutron radiotherapy. The software development efforts are described further in a separate 
article in this Annual Report. 
5. Design and initiation of construction of an advanced epithennal-neutron beam extraction 
facility for the TRIGATM research reactor at WSU. 
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INTRODUCTION 
A CRADA between the INEEL and a 
private company, NTL, was established in 
1996 to M h e r  the development of BNCT. 
This CRADA, which was renewed for a 
second three-year term in 1999, is focused 
on the development of key technologies 
required for clinical implementation of 
BNCT using various promising alternative 
boron agents. 
NTL has established a laboratory for the 
synthesis, under U.S. FDA approved current 
Good Manufacturing Practices (cGMP) 
guidelines, of key boron intermediates and 
final boron agents for BNCT. The company 
has focused initially on the development of 
the compound GB-10 (Na2BloHlo) as the 
first boron agent of interest. An 
Investigational New Drug (IND) application 
for GB-10 has been filed and approved by 
the FDA for a Phase I human biodistribution 
trial in patients with non-small cell lung 
cancer and glioblastoma multiforme at UW 
under the direction of Professor Keith 
Stelzer, Principal Investigator (PI). These 
trials are funded by NTL under a contract 
with the UW, Department of Radiation 
Oncology, and the initial phases are nearing 
completion. Initial results show that boron- 
10 concentrations on the order of 100 
micrograms per gram (100 ppm) can be 
achieved and maintained in blood with no 
indication of toxicity. 
Following the planned completion of the 
biodistribution studies in mid-2000, -an 
approved Phase ID1 trial of BNCT- 
augmented FNT will be initiated using GB- 
10. These studies will also be sponsored by 
NTL, with in-kind technical support from 
the INEEL. They will include treatment of 
inoperable non-small cell lung tumors 
(Stage IIIA and B), and glioblastoma 
multiforme using the cyclotron-based fast 
neutron radiotherapy facility at the UW 
(Figure 4). These trials will be 
supplemented by epithermal-neutron-based 
radiobiological research using the new 
epithermal-neutron beam facility that is 
currently under construction at WSU. 
Professor Patrick Gavin at WSU will be the 
PI for radiobiological and preclinical 
(nonclinical) studies of new boron agents in 
large animal studies using the new beam. 
RECENT ACCOMPLISHMENTS 
The partners to the INEEL/NTL CRADA 
and their university affiliates have achieved 
a number of significant milestones. These 
include: 
1. Development of a modified neutron 
production target assembly for the UW 
facility that provides improved 
performance of the system for 
applications involving BNCT-enhanced 
FNT. Prior efforts'-3 to modify light-ion 
accelerator based FNT facilities for 
optimization of BNCT enhancement 
have generally focused either on 
degradation of the charged particle beam 
before it impinges on the neutron 
production region of the target, or on 
partial moderation and filtration of the 
neutron beam after it exits the target. 
These projects have produced neutron 
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Figure 4. Treatment gantry at UW Neutron Therapy Clinic. 
beams that offer enhanced BNCT 
components of the total dose, but this 
has tended to be accomplished at the 
expense of degradation of the 
performance of the background fast- 
neutron beam, typically manifested by a 
reduction in the half-value depth for the 
fast-neutron dose component. 
However, a more promising approach 
involving a redesign of the neutron 
production target itself was explored in 
an extensive computational investigation 
conducted by the INEEL, and a 
prototype target assembly -was 
successfully tested at u+. The 
modified neutron production target 
offers an improved BNCT-enhancement 
component with only minimal sacrifice 
of the desirable fast-neutron depth-dose 
characteristics of the neutron beam 
produced by the standard UW neutron 
production target. 
Development of a safe and practical 
process for the laboratory synthesis of 
decaborane (B10H14), a key precursor for 
several advanced boron agents of 
interest. Limited quantities have been 
available commercially in the past from 
a few suppliers, but this is no longer the 
case. In addition, decaborane 
synthesized from boron that is enriched 
in the isotope 'OB is required for BNCT 
purposes. Chemists at the INEEL 
developed an improved process for 
synthesizing enriched decaborane in a 
manner that can be safely and efficiently 
done in a standard chemical laboratory. 
This process has been transferred under 
license to NTL. 
3. Establishment, under U.S. FDA cGMP 
guidelines, of a process for synthesizing 
decaborane as well as the first derived 
boron agent of interest for human 
clinical trials of NCT-enhanced FNT for 
certain types of lung and brain tumors. 
t 
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The decaborane synthesis process 
licensed by INEEL to NTL is now hl ly  
operational, under the FDA cGMP 
I!v guidlines in laboratories operated by 
NTL. In addition, GB-10 is also being 
synthesized and packaged as a sterile, 
injectable drug, and packaged for human 
applications. As noted previously, NTL 
has obtained FDA approval of an IND to 
conduct initial human biodistribution 
studies of GB-10 for treatment of non- 
small cell lung tumors and glioblastoma 
multiforme, and for the fast neutron 
NCT-augmented brain tumor radiation 
trials. 
4. Enhancement of computational 
dosimetry and treatment planning 
software originally developed by INEEL 
for epithermal-neutron BNCT to allow 
applicability to all forms of neutron 
radiotherapy. The software development 
efforts are described further in a separate 
article in this Annual Report. 
5. Design and initiation of construction of 
an advanced epithermal-neutron beam 
extraction facility for the TRIGATM 
research reactor at WSU, as described 
elsewhere in this Annual Report. 
FUTURE WORK 
Future activities under the INEEL/NTL 
CRADA will build on the accomplishments 
described above, and will be focused in the 
conduct of preclinical research and clinical 
trials by the partners and university 
affiliates. NTL will have the lead 
responsibility for the following activities: 
1. Provide the boron agent GB-10, as well 
as financial sponsorship, for ongoing 
biodistribution and radiation trials at 
UW. 
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2. Provide the boron agent GB-10, and 
financial sponsorship to WSU for 
preclinical normal tissue tolerance 
studies in support of BNCT-enhanced 
fast neutron radiotherapy trials at UW. 
Furthermore, over the period of this 
CRADA, it is anticipated that additional 
boron drug agents will be supplied to 
WSU by NTL for continued preclinical 
screening and research using the new 
epithermal neutron beam at WSU. 
3.  Establish the WSU facilities for 
determing the pharmacokinetics and 
toxicity studies for new boron agents 
conducted under Good Laboratory 
Practices. 
4. Support preclinical brain tumor radiation 
studies at the WSU epithermal beam, for 
GB-10 and for next generation boron 
agents. 
5. Initiate Phase ID1 radiotherapy trials of 
GB-10 with the fast neutron 
radiotherapy facility at the UW. These 
trials will start with glioblastoma 
multiforme brain tumor patients and be 
followed by both Stage IIIA and Stage 
IIIB inoperable lung tumor patients. 
The INEEL will, in turn, have continued 
responsibility for the following in-kind 
support activities: 
1. Perform tissue-boron and blood-boron 
analysis of biological samples submitted 
by NTL and its subcontractors. 
2. Perform various independent chemical 
analyses of boron agent samples 
submitted by NTL. 
3. Provide the SERA computational 
dosimetry and treatment planning 
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software package to UW. Assist UW 2. C. Kota, R.L. Maughn, J. Bunneister, 
personnel with the use of SERA as and J.D. Forman, "A Modified Fast 
needed, and assist with development of Neutron Therapy Beam for Boron 
treatment plans for patients entered into Neutron Capture Enhanced Fast Neutron 
BNCT-enhanced FNT protocols 
sponsored by NTL at UW. 
4. Assist as needed with continued 
performance characterization and 
dosimetry of the new BNCT neutron 
production target assembly that has been 
developed for the UW FNT facility. In 
addition, INEEL will provide 
computational and experimental 
dosimetry support for the planned 
animal irradiations at WSU. 
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To: Richard J. Wiersema4Viersema@pacbelI.net> 
CC: John A Alexander/JAWCCOl/INEEUUS@INEL, David W NiggIDWNICCOl/INEEUUS@INEL 
Subject: Notice of CRADA No. 95-CR-09 Completion 
Dear Dr. Richard J. Wiersema, 
This notifies you as NT LLC's Chief Scientific Officer that our first CRADA No. 95-CR-09 entitled 
"Commercial Clinical Application of Boron Neutron Capture therapy" is completed and that the established 
completion date is September 3, 1999. 
With regards to CRADA 95-CR-09 Articles VII, XI, XII, and XIV; both Proprietary Information obligations 
(Article VII) and publication obligations (Article XII) have been met, reports and abstracts have been 
delivered (Article XI), and Subject Inventions were disclosed as per Article XIV. The final report is 
attached. 
Final Report - CI-INICAL IMPLEMEN 
Please reply back to me regarding your concurrence. If I do not hear from you by June 5, 2000, your 
concurrence will be assumed. 
Sincerely, 
Tom Ulrich 
To: Professor Patrick R. Gavin <prg@vetrned.wsu.edu> 
CC: John A Alexander/JAWCCOI/INEEUUS@INEL, David W Nigg/DWN/CCOl/INEEUUS@INEL 
Subject: Notice of CRADA No. 95-CR-09 Completion 
Dear Professor Patrick R. Gavin, 
This notifies you -- as the principle investigator for CRADA No. 95-CR-09 -- and Washington States 
University that this CRADA entitled "Commercial Clinical Application of Boron Neutron Capture therapy" is 
completed and that the established completion date is September 3, 1999. 
With regards to CRADA 95-CR-09 Articles VII, XI, XII, and XIV; both Proprietary Information obligations 
(Article VII) and publication obligations (Article XII) have been met, reports and abstracts have been 
delivered (Article XI), and Subject lnventions were disclosed as per Article XIV. The final report and list of 
Subject lnventions are attached. 
&* Q Q 
Final Report - CLINICAL IMPLEMEN CRADA No 95-CR-09 Subject lnven 
Please reply back to me regarding your concurrence. If I do not hear from you by June 5,2000, your 
concurrence will be assumed. 
Sincerely, 
Tom Ulrich 
Account Executive 
Bechtel BWXT Idaho, LLC 
P.O. Box 1625 
Idaho Falls, ID 83415 
Voice: (208) 526-7282 
Fax: (208) 526-0828 
1 -7-7' A" & L C ,  ri,,s,amDpecn .nl, d l ? . < ~ G r r v .  raaonc. w8sfi~a'foi,. eciu, 
McCOYLS@inel. gov, dwn@inel: gov, robert .marlay@hq. doe. gov, 
"Dr. Roland Hirsch" <Roland.Hirsch@oer.doe.gov>, shelly@chem.ucla.edu, 
Keith@radonc.washington.edu, Griffin@merry.radonc.washington.edu, 
tu2@inel.gov, gtripard@wsunix.wsu.edu, jrv@inel.gov, dew@inel.gov, 
fjw@inel.qov 
From: "~ichard J. -~iersema" <wiersema@pacbell .net> 
Subject: Where is Neutron Therapies?? 
'I.0 all: 
The Neutron Therapies activities are now operational in San Diego, where we will be making 
the GB-10 boron agent for human use. The particulars for contacting me are as follows: 
Neutron Therapies Inc. 
5340 E a s t g a t e  M a l l  
San  Diego, CA 92121 
Telephone: (619) 678-8683 
Fax: (619) 678-8615 
e-Mail: wiersema@pacbell.net 
(I will have the old rwionix@ida.net forwarded to the new address for about a month) 
P.S. The date of Monday, May 19, 1997 is important!!! 
The dog irradiation studies started at UW on the fast neutron beam for a spontaneous lung 
tumor with GB-10. The dog's name is BOOMER. 
Dick Wiersema 
Neutron Therapies Inc. 
Printed for Tom Ulrich <tu2@inel.gov> 1 
